Log in or Sign up for Free to view tailored content for your specialty!
Practice Management News
'Denials must not be a mystery': AMA adopts prior authorization policies
The AMA House of Delegates adopted two new policies aiming to reform prior authorization and the burden it causes patients and physicians.
‘Concerning signs’ appear as biosimilars show inability to reduce out-of-pocket costs
Biosimilars have generated billions of dollars of savings for the health care complex, but they have not had an impact on out-of-pocket expenses for patients with private insurance, according to findings published in JAMA Health Forum.
Log in or Sign up for Free to view tailored content for your specialty!
TRAQ score predicts readiness to transition from pediatric to adult rheumatology care
Pediatric rheumatology patients could be considered ready to transfer to adult care if they score greater than 4 on the Transition Readiness Assessment Questionnaire, according to data published in Rheumatology.
Lab results, symptom tracking top list of key metrics among rheumatology patients
The ability to view laboratory results, track symptoms and sharing them with a provider were rated as the most useful potential app functions by patients with rheumatic and musculoskeletal diseases, according to data.
Q&A: Physicians call for federal action to combat rise in cyberattacks
On May 8, the health care organization Ascension experienced a cyberattack that disrupted access to its electronic health care records, patient portals, phones and systems used to order tests, medications and procedures.
Financial independence: ‘Enough’ is absolute, not relative to anyone else
Financial independence is the holy grail, which affords one to work for the sake of working with the peace of mind of knowing they are no longer dependent on a paycheck to maintain their lifestyle.
Mark Cuban’s Cost Plus Drug Company ‘flying under the radar’ after 2 years
The Mark Cuban Cost Plus Drug Company launched in January 2022 to a flurry of promises, curiosity, and a certain guarded optimism among experts regarding its potential to lower medication prices for patients.
Uplizna reduces IgG4 related disease flare risk by 87% in MITIGATE trial
The monoclonal antibody Uplizna met key endpoints in a phase 3 trial for the treatment of IgG4-related disease, marking the first time a placebo-controlled study has shown benefit in the condition, according to a press release from Amgen.
Access to surgery where rheumatic heart disease is endemic a barrier to improving survival
Much of the mortality in rheumatic heart disease was attributable to heart failure, and was significantly reduced by interventional treatment, which may stand as a barrier to improving mortality in lower-income countries, data show.
VIDEO: Inflammation ‘coming to the forefront’ of cardiovascular care
In this Healio video exclusive, Michael S. Garshick, MD, MS, discusses the role of inflammation in heart disease and how it has become a treatment target.
-
Headline News
Biden administration bans medical debt from credit reports, wipes millions in debt
January 07, 20252 min read -
Headline News
Cardiometabolic benefits of time-restricted eating may go beyond weight loss
January 08, 20253 min read -
Headline News
GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity
December 09, 20243 min read
-
Headline News
Biden administration bans medical debt from credit reports, wipes millions in debt
January 07, 20252 min read -
Headline News
Cardiometabolic benefits of time-restricted eating may go beyond weight loss
January 08, 20253 min read -
Headline News
GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity
December 09, 20243 min read